However, the mOS in their study was 52
However, the mOS in their study was 52.0 months, which was higher than our mOS of 36.0 months. gefitinib retreatment beyond disease progression may be an effective and tolerable approach for NSCLC individuals with sensitive mutations. amplification.3 We previously4,5 showed that TKI retreatment beyond progression (TBP) could help to achieve long-term survival in selected patients….